XERS XERIS BIOPHARMA HOLDINGS INC revenue, earnings and financials

For the quarter ended June 30, 2026, XERIS BIOPHARMA HOLDINGS INC reported revenue of $92.1M (up 28.7% from a year earlier), net income of −$31.1M and diluted EPS of −$0.18; over the last four quarters revenue was $335M and net income −$17.2M; for the fiscal year ended December 2025 revenue was $292M, up 43.7% on the year before.

XERS annual revenue and earnings

• Fiscal year ended Dec 2025: revenue $292M, gross profit n/a, operating income $24.9M, net income $554K (margin 0.2%), EPS $0.00
• Fiscal year ended Dec 2024: revenue $203M, gross profit n/a, operating income −$33.6M, net income −$54.8M (margin -27.0%), EPS −$0.37
• Fiscal year ended Dec 2023: revenue $164M, gross profit n/a, operating income −$44.0M, net income −$62.3M (margin -38.0%), EPS −$0.45
• Fiscal year ended Dec 2022: revenue $110M, gross profit n/a, operating income −$81.9M, net income −$94.7M (margin -85.9%), EPS −$0.70
• Fiscal year ended Dec 2021: revenue $49.6M, gross profit n/a, operating income −$115M, net income −$123M (margin -247.5%), EPS −$1.55

XERS quarterly revenue and earnings

• Quarter ended Jun 30, 2026: revenue $92.1M (up 28.7% year over year), net income −$31.1M, EPS −$0.18
• Quarter ended Mar 31, 2026: revenue $83.1M (up 38.3% year over year), net income $2.23M, EPS $0.01
• Quarter ended Dec 31, 2025 (from the annual report): revenue $85.8M (up 42.8% year over year), net income $11.1M, EPS $0.07
• Quarter ended Sep 30, 2025: revenue $74.4M (up 37.1% year over year), net income $621K, EPS $0.00
• Quarter ended Jun 30, 2025: revenue $71.5M (up 48.8% year over year), net income −$1.93M, EPS −$0.01
• Quarter ended Mar 31, 2025: revenue $60.1M (up 47.9% year over year), net income −$9.22M, EPS −$0.06
• Quarter ended Dec 31, 2024 (from the annual report): revenue $60.1M (up 35.4% year over year), net income −$5.11M, EPS −$0.02
• Quarter ended Sep 30, 2024: revenue $54.3M (up 12.3% year over year), net income −$15.7M, EPS −$0.11
• Quarter ended Jun 30, 2024: revenue $48.1M (up 26.5% year over year), net income −$15.0M, EPS −$0.10
• Quarter ended Mar 31, 2024: revenue $40.6M (up 22.4% year over year), net income −$19.0M, EPS −$0.14
• Quarter ended Dec 31, 2023 (from the annual report): revenue $44.4M (up 33.9% year over year), net income −$13.4M, EPS −$0.10
• Quarter ended Sep 30, 2023: revenue $48.3M (up 62.6% year over year), net income −$12.2M, EPS −$0.09
• Quarter ended Jun 30, 2023: revenue $38.0M (up 50.2% year over year), net income −$19.8M, EPS −$0.14
• Quarter ended Mar 31, 2023: revenue $33.2M (up 50.4% year over year), net income −$16.8M, EPS −$0.12
• Quarter ended Dec 31, 2022 (from the annual report): revenue $33.1M (up 54.7% year over year), net income −$12.9M, EPS −$0.10
• Quarter ended Sep 30, 2022: revenue $29.7M (up 168.8% year over year), net income −$21.8M, EPS −$0.16
• Quarter ended Jun 30, 2022: revenue $25.3M (up 184.1% year over year), net income −$26.2M, EPS −$0.19
• Quarter ended Mar 31, 2022: revenue $22.1M (up 169.3% year over year), net income −$33.7M, EPS −$0.25
• Quarter ended Dec 31, 2021 (from the annual report): revenue $21.4M, net income −$50.8M, EPS −$0.45
• Quarter ended Sep 30, 2021: revenue $11.1M, net income −$26.0M, EPS −$0.39

XERS cash flow, buybacks and dividends

• Fiscal year ended Dec 2025: operating cash flow $28.6M, share buybacks n/a
• Fiscal year ended Dec 2024: operating cash flow −$37.0M, share buybacks n/a
• Fiscal year ended Dec 2023: operating cash flow −$47.0M, share buybacks n/a
• Fiscal year ended Dec 2022: operating cash flow −$103M, share buybacks n/a
• Fiscal year ended Dec 2021: operating cash flow −$95.5M, share buybacks n/a

XERS balance sheet

• Jun 30, 2026: cash $122M, total assets $412M, total liabilities $422M, shareholders' equity −$9.73M, long-term debt $189M
• Mar 31, 2026: cash $112M, total assets $392M, total liabilities $379M, shareholders' equity $13.0M, long-term debt $221M
• Dec 31, 2025: cash $111M, total assets $384M, total liabilities $370M, shareholders' equity $13.7M, long-term debt $220M
• Sep 30, 2025: cash $91.6M, total assets $370M, total liabilities $371M, shareholders' equity −$861K, long-term debt $219M
• Jun 30, 2025: cash $59.3M, total assets $335M, total liabilities $354M, shareholders' equity −$19.3M, long-term debt $219M
• Mar 31, 2025: cash $58.4M, total assets $315M, total liabilities $351M, shareholders' equity −$35.1M, long-term debt $218M
• Dec 31, 2024: cash $71.6M, total assets $323M, total liabilities $353M, shareholders' equity −$29.6M, long-term debt $217M
• Sep 30, 2024: cash $59.2M, total assets $321M, total liabilities $349M, shareholders' equity −$28.3M

What is XERS's revenue?

XERIS BIOPHARMA HOLDINGS INC reported $335M of revenue over its last four quarters, through June 30, 2026.

Is XERS profitable?

No. XERIS BIOPHARMA HOLDINGS INC lost $17.2M over the last four quarters.

What is XERS's EPS?

Diluted earnings per share over the last four quarters were −$0.10; −$0.18 in the latest quarter.

XERS ownership and insider trades · All stocks